common.study.topics.clinical

Experimental Tratment for Intracranial Hemorrhage

common.study.values.description

Trial of Andexanet in ICH Patients Receiving an Oral FXa Inhibitor

Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet versus usual standard of care in patients with intracranial hemorrhage anticoagulated with a direct oral anticoagulant

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - andexanet alfa

Andexanet is a recombinant version of human FXa

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 4 Randomized Clinical Trial of Andexanet Alfa [Andexanet Alfa for Injection] in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor

common.study.values.clinical-trial-id

NCT03661528

participant.views.study.view.id

bqx7Ga